Skip to main content

Talvey Disease Interactions

There are 2 disease interactions with Talvey (talquetamab).

Moderate

Bispecific T-cell engagers (applies to Talvey) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Teclistamab and talquetamab can cause severe, life-threatening, or fatal infections. Patients should be monitored for signs and symptoms of infection prior to and during treatment. Any infection should be treated appropriately. Administer prophylactic antimicrobials according to clinical guidelines.

References

  1. (2022) "Product Information. Tecvayli (teclistamab)." Janssen Biotech, Inc.
  2. (2023) "Product Information. Talvey (talquetamab)." Janssen Biotech, Inc.
Moderate

Bispecific T-cell engagers (applies to Talvey) renal/hepatic

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Renal Dysfunction

The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.

References

  1. (2022) "Product Information. Tecvayli (teclistamab)." Janssen Biotech, Inc.
  2. (2023) "Product Information. Talvey (talquetamab)." Janssen Biotech, Inc.

Talvey drug interactions

There are 392 drug interactions with Talvey (talquetamab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer